Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $31.37 USD
Change Today -0.52 / -1.63%
Volume 22.6M
PFE On Other Exchanges
SIX Swiss Ex
Sao Paulo
As of 8:04 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Mikael Dolsten M.D., Ph.D.

President of Worldwide Research & Development,Pfizer Inc.
AgeTotal Calculated CompensationThis person is connected to 49 board members in 2 different organizations across 5 different industries.

See Board Relationships
As of Fiscal Year 2014


Prof. Mikael Dolste, MD, Ph.D., has been the President of Worldwide Research and Development at Pfizer Inc. since December 2010. Prior to joining Pfizer in 2009, Prof. Dolsten was Senior vice president of Wyeth and President of Wyeth Research where he was responsible for the global R&D division and led scientists across the US, Europe and Asia. Before joining Wyeth, he served as Executive vice president at Boehringer Ingelheim, where he was responsible for worldwide ...

Read Full Background

Corporate Headquarters*

235 East 42nd Street
New York, New York 10017

United States

Phone: 212-733-2323
Fax: --

Board Members Memberships*



Unknown/Other Education
Weizmann Institute Of Science
Lund University
Lund University

Other Affiliations*

Annual Compensation*

Total Annual Compensation$1,177,500

Stock Options*

Restricted Stock Awards$1,863,860
All Other Compensation$156,180
Exercisable Options530,757
Exercisable Options Value$6,678,912
Unexercisable Options1,051,432
Unexercisable Options Value$5,456,034
Total Value of Options$12,134,946
Total Number of Options1,582,189

Total Compensation*

Total Annual Cash Compensation$2,633,680
Total Short Term Compensation$1,177,500
Other Long Term Compensation$2,020,040
Total Calculated Compensation$7,275,054
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PFE:US $31.37 USD -0.52


John C. Martin Ph.D.Chairman and Chief Executive Officer
Gilead Sciences Inc.
Paul Bulcke B.E.Chief Executive Officer, Member of Executive Board, Director and Member of Chairman's & Corporate Governance Committee
Nestlé S.A.
Alan George Lafley Chairman, Chief Executive Officer, President and Member of Proxy Committee
The Procter & Gamble Company
Marijn E. Dekkers Ph.D.Chairman of Management Board and Chief Executive Officer
Bayer AG
Alex Gorsky Chairman, Chief Executive Officer, Chairman of Executive Committee and Chairman of Finance Committee
Johnson & Johnson
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PFIZER INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at